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http:WHAT THIS PAPER ADDS
The 30-day outcomes of endovascular aneurysm sealing (EVAS) for infrarenal non-ruptured abdominal aortic
aneurysm (AAA) in a single centre are presented. The report focuses on intra- and perioperative complications,
the learning curve of the procedure, and treatment of early endograft related issues. EVAS in this cohort of
patients with challenging aortic anatomy, was associated with low rates of early endoleak and reintervention in
patients treated for infrarenal AAA.Objective: Endovascular aneurysm sealing (EVAS) has been proposed as a novel alternative to endovascular
aneurysm repair (EVAR) in patients with infrarenal abdominal aortic aneurysms (AAA). The early clinical
experience, technical reﬁnements, and learning curve of EVAS in the treatment of AAA at a single institution are
presented.
Methods: One-hundred and ﬁve patients were treated with EVAS between March 2013 and November 2014.
Prospective data were recorded on consecutive patients receiving EVAS. Data included demographics,
preoperative aneurysm morphology, and 30-day outcomes, including rates of endoleak, limb occlusion,
reintervention, and death. Postoperative imaging consisted of duplex ultrasound and computed tomographic
angiography.
Results: The mean age of the cohort was 76  8 years and 12% were female. Adverse neck morphology was
present in 72 (69%) patients, including aneurysm neck length <10 mm (20%), neck diameter >32 mm (18%),
b-angulation >60 (21%), and conical aneurysm neck (51%). There was one death within 30 days. The incidence
of Type 1 endoleak within 30 days was 4% (n ¼ 4); all were treated successfully with transcatheter embolisation.
All four proximal endoleaks were associated with technical issues that resulted in procedure reﬁnement, and all
were in patients with adverse proximal aortic necks. The persistent Type 1 endoleak rate at 30 days was 0% and
there were no Type 2 or Type 3 endoleaks. Angioplasty and adjunctive stenting were performed for postoperative
limb stenosis in three patients (3%).
Conclusions: EVAS appears to be associated with reasonable 30-day outcomes despite the necessity of
procedural evolution in the early adoption of this technique. EVAS appears to be applicable to patients with
challenging aortic morphology and endoleak rates should reduce with procedural experience. The utility of EVAS
will be deﬁned by the durability of the device in long-term follow-up, although the absence of Type 2 endoleaks is
encouraging.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovascular aneurysm repair (EVAR) has reduced periop-
erative risk compared with open repair of abdominal aortic
aneurysm (AAA).1e3 However, concerns persist around long-B and JLDB contributed equally to this study.
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//dx.doi.org/10.1016/j.ejvs.2015.03.024term durability,4e6 and the continuing need for intensive
endograft surveillance to prevent late aortic rupture. Rates
of aortic reintervention remain high after EVAR, particularly
in cases of adverse aortic morphology.7,8 Hostile neck
morphology including short, angulated, conical, or wide
necks is associated with higher rates of proximal Type 1
endoleak, reintervention, and aneurysm-related mortal-
ity.9e11 Type 2 endoleaks are associated with increased
rates of reintervention and aortic complications.12,13 Their
management and clinical signiﬁcance is controversial but
their presence contributes towards the burden of post-
endograft surveillance.
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system (Endologix, Irvine, CA, USA) offers a novel approach
for endovascular treatment of infrarenal AAA. The tech-
nique uses polymer-ﬁlled endobags to achieve anatomical
ﬁxation in the aneurysm sac, while the same endobags
create a sealing zone in the infrarenal aortic neck and the
iliac arteries (Fig. 1). The endobags ﬁll the aneurysm sac and
EVAS has the potential to reduce the incidence of Type 2
endoleak after endovascular treatment of AAA. EVAS
potentially offers a new paradigm in the treatment of AAA,
but like all new techniques will be associated with a novel
set of complications that need to be deﬁned and mitigated.
Previous morphological analysis has suggested that the
Nellix system may be able to treat a greater proportion of
patients within the manufacturer’s indications for use (IFU)
than many EVAR systems.14 Early data from small series
suggest that EVAS may be used to treat hostile neck anat-
omy with good short-term outcomes.15,16 The present study
describes 30-day outcomes of EVAS for infrarenal non-
ruptured abdominal aortic aneurysm (AAA) in a single
centre. The report focuses on intra- and perioperative
complications, the learning curve of the procedure, and
treatment of early endograft-related issues.
METHODS
Study population
The EVAS programme started in March 2013 after com-
mercialisation of the endograft following award of a CE
mark. All patients with non-ruptured infrarenal AAA treated
with the Nellix device between March 1, 2013, and
November 30, 2014 were included. Data were recorded
prospectively and included demographics, aneurysm
morphology, procedural details, and early surveillance out-
comes. The 30-day outcomes are reported according to
consensus reporting standards.17 Speciﬁc ethical approvalFigure 1. (A) Nellix system deployed within an infrarenal abdom-
inal aortic aneurysm. (B) Endobag insufﬂation and aneurysm
sealing.for this study was not required because the analyses un-
dertaken used data collected for routine clinical care (UK
National Research Ethics Service guidance). The ﬁrst 10
patients treated with the Nellix graft were within the
manufacturer’s IFU, while the graft was in the early phase
of commercialisation, and the procedure was being tech-
nically reﬁned. During this time, bifurcated endovascular
systems were preferentially used in patients with anatomy
compliant with the manufacturer’s IFU for the Endurant
(Medtronic Vascular, Santa Rosa, CA, USA) and Zenith (Cook
Medical, Bloomington, IN, USA) endografts. As experience
built, patients with more challenging neck anatomy were
treated outside of IFU after speciﬁc consent.Endovascular aneurysm sealing and follow-up
The technique used for EVAS changed during the study
period as experience was gained, complications were re-
ported globally, and the procedure was reﬁned. The current
procedure used at the Vascular Institute at St George’s
Hospital, London, UK is brieﬂy described. A 3D workstation
(3mensio Medical Imaging BV, Bilthoven, The Netherlands)
was used to deﬁne pre-procedure aortic morphology with
emphasis on the centreline distance between renal arteries
and aortic bifurcation (used for calculation of device length)
and the volume of the ﬂow lumen between renal arteries
and iliac bifurcations (used to estimate polymer ﬁll volume).
A percutaneous puncture was made in the common
femoral arteries and two Proglide (Abbott Vascular, Abbott
Park, IL, USA) closure devices deployed.18 Unfractionated
heparin (5000 units) was administered intravenously. Two
14F sheaths (Cook Medical, Bloomington, IN, USA) were
inserted over Lunderqvist wires (Cook Medical) and a cali-
brated angiogram obtained to supplement information
provided by preoperative planning and deﬁne the lengths of
the Nellix system required. Usually, the lengths were
deﬁned from lowermost renal artery to iliac bifurcation with
a single line technique using a calibrated catheter. The Nellix
devices (Endologix, Irvine, CA, USA) were inserted through
the common femoral artery bilaterally, and advanced over a
wire into a position at the lowermost renal ostia. Parallax
was corrected (using the sheath markers) and an angiogram
was obtained through the integrated angiogram ports in the
nose cone of the device. After retracting the covering
sheath, the stentgrafts were positioned at the level of the
lowermost renal artery and stents deployed by simulta-
neous inﬂation of the Nellix balloons to 7atm. The Nellix
balloons remained inﬂated for an estimated 5 minutes to
ensure maximum stability of the endograft system until
primary polymer cure.
After stent deployment, a “preﬁll technique” was used to
inﬂate the integrated endobags with saline to 180 mmHg.
At this juncture, an angiogram was obtained to ensure that
the aneurysm was sealed. If there was an endoleak, saline
was instilled to a maximum pressure of 220 mmHg. After
sealing was demonstrated, the saline was aspirated and was
replaced with an equal volume of aqueous polyethylene
glycol-based polymer. Following polymer cure, the Nellix
Endovascular Aneurysm Sealing 159balloons were deﬂated and a further angiogram was per-
formed to determine whether the aneurysm was sealed.
The primary ﬁll lines were removed and the pressures were
checked in the endobags using the secondary ﬁll lines and a
small volume of saline. If there was a failure of sealing or if
pressures in the endobags were lower than 180 mmHg on
saline instillation (<1 mL to create a hydraulic column into
the endobag), further polymer was added to the endobags
at this stage, deﬁned by secondary “preﬁll” volumes.
Following ﬁnal polymer cure, the delivery devices were
removed. Post dilatation of the stents was routinely per-
formed using a 10  40 mm angioplasty balloon (Cook
Medical) inﬂated to 7atm.
Completion angiography was used to deﬁne aneurysm
seal and patency of the system. In the presence of adverse
angulation between the EVAS stentgraft and the iliac vessel
wall, additional uncovered bare metal self-expandable
stentgrafts were deployed (Zilver, Cook Medical). The
postoperative surveillance protocol speciﬁed a post-
operative duplex and CT angiography prior to discharge and
within 30 days. At present the surveillance requirements of
the Nellix system remain to be deﬁned. Patients are
therefore monitored with both duplex and CT scans post-
operatively and then at a minimum of 6 months, 12
months, and yearly thereafter.19,20 Duplex surveillance
assessed stent patency, presence of endoleak, and aortic sac
size change alongside percutaneous access complications
such as pseudoaneurysms.20 Scans were performed by
specialised vascular sonographers using a Philips IU22 ma-
chine (Philips Healthcare, Eindoven, The Netherlands) and a
C5e1 MHz curvilinear array following the departmental
standard protocol for conventional EVAR surveillance.
Postoperative CT images were acquired using the GE
Lightspeed VCT 64 Slice Scanner (GE Healthcare, Waukesha,
WI, USA). Image sets extended from the thoracic inlet to
the bifurcation of the common femoral artery with a slice
thickness of 0.625 mm. Intravenous injection of 90 mL of
Omnipaque 300 (Iohexol 300/Omnipaque 300; Sanoﬁ-
Winthrop, NY, USA) was given according to institutional
protocol. All patients were prescribed a single antiplatelet
agent providing there were no contraindications.Deﬁnitions and data analysis
All deaths within 30 days were considered to be aneurysm-
related as per consensus reporting standards, and reinter-
vention was deﬁned as any secondary procedure performed
to maintain aneurysm exclusion or distal perfusion.17
Endoleaks were classiﬁed according to established deﬁni-
tions.21 Adverse neck morphology was deﬁned according to
parameters in the manufacturer’s instructions for use
including neck length <10 mm, maximum neck diameter
>32 mm, and an angle of neck to body of the aneurysm (b-
angulation) 60. Conical aneurysm neck was deﬁned as an
aortic diameter 15 mm below the lowest renal artery 10%
larger than the aortic diameter at the lowest renal artery.11
Continuous variables are expressed as median and range
or as mean  standard deviation where appropriate.Categorical variables are presented as numbers with per-
centages. Differences between the ﬁrst and second halves
of the series were assessed using a combination of unpaired
t tests and chi-square test, for continuous and categorical
data, respectively. A p value of < .05 indicated a difference
of statistical signiﬁcance. All statistical analyses were per-
formed with the use of SPSS version 21.0 (SPSS Inc., Chi-
cago, IL, USA).
RESULTS
A total of 105 patients underwent EVAS with the Nellix
device for infrarenal non-ruptured AAA between March 1,
2013, and November 30, 2014. All patients were included
and the results reﬂect the entire experience from initial
graft utilisation. During the study period, 82 conventional
EVAR procedures and two primary open repairs were per-
formed for non-ruptured infrarenal aneurysms.
The mean age of patients was 76  8 years, and over
one-third of patients were octogenarians. Over three-
quarters were ASA 4 and 12% were female. The median
Society of Vascular Surgery/International Society for Car-
dioVascular Surgery score was 8 (IQR 6e10). Eight patients
were treated for symptomatic aneurysms, and one patient
had a mycotic aneurysm with challenging proximal neck
anatomy, unsuitable for a conventional bifurcated graft. Co-
existing unilateral iliac artery aneurysms were present in
two patients treated; one further patient had aorto-bi-iliac
aneurysms. All patients had a postoperative duplex prior to
discharge and within 30 days; 98 (93%) patients underwent
CT angiography within 30 days. No signiﬁcant change was
observed between preoperative and renal function on
discharge (eGFR 77.5  32.6 versus 80.3  40.5, p ¼ .25).
The median length of stay was 2 days (IQR 2e5).
The median aneurysm diameter was 6.1 cm (IQR 5.8e
6.7) and adverse neck morphology was present in 72/105
(69%) patients (Table 1). Features of adverse neck
morphology included short (<10 mm) aneurysm neck
length in 21/105 (20%), neck diameter >32 mm in 19/105
(18%), b-angulation >60 in 22/105 (21%), and conical
aneurysm neck in 72/105 (69%). Two or more features of
adverse neck morphology were present in 46 (44%) pa-
tients. There was an increase in the proportion of patients
with a short aneurysm neck length from 17% in the ﬁrst half
of the experience to 23% in the second half (p ¼ .49). The
proportion of patients with neck diameter >32 mm (21% to
15%, p ¼ .42) and b-angulation >60 (23% to 19%, p ¼ .63)
was lower in the latter half of the experience reported.
Overall, 53 (50%) patients had a conical neck and the ma-
jority were treated in the second half (21/52 versus 32/53,
p ¼ .04).30-day mortality
There was one death on day 18 following EVAS for which
the cause of death was not determined. The patient
collapsed at home and no post mortem examination was
performed. The postoperative CT scan demonstrated good
graft position in a para-renal aneurysm and no endoleak.
Table 1. Baseline demographics and aneurysm morphology.
Overall cohort
n ¼ 105
Age, median (IQR), years 77.3 (71.1e81.5)
Female, n (%) 13 (12)
Diabetes mellitus, n (%) 13 (12)
Smoking history, n (%) 74 (71)
Hypertension, n (%) 82 (78)
Coronary artery disease, n (%) 36 (34)
Cerebrovascular accident, n (%) 13 (12)
eGFR 72.4 (58.5e89.5)
Max sac diameter, median (range), cm 6.1 (5.8e6.7)
Neck length, median (range), mm 22 (14e33)
Neck length <10 mm, n (%) 21 (20)
Neck diameter, median (range), mm 27 (24e30)
Neck diameter >32 mm, n (%) 19 (18)
b neck angulation 42 (30e58)
b neck angulation >60, n (%) 22 (21)
Conical aneurysm neck 53 (51)
eGFR indicates estimated glomerular ﬁltration rate.
Coronary artery disease deﬁned as history of acute coronary
syndrome, coronary revascularisation or stable/unstable angina;
cerebrovascular accident, history of transient ischaemic attack,
or stroke.
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Four proximal Type 1 endoleaks were identiﬁed on post-
operative imaging; all in patients treated with hostile
proximal aortic neck morphology (Table 2), and all in the
second half of the overall experience. After retrospective
review, it was considered that all four cases were caused by
technical issues during the procedure. In two cases, the
Nellix system was deployed lower in the aortic neck than
planned. Both cases of low deployment were caused by
inadequate correction of parallax in angulated necks
(Fig. 2). In subsequent cases, modiﬁcation of the procedure
ensured adequate correction of parallax by using the sheath
markers of the Nellix system to ensure that the X-ray tube
was positioned perpendicular to the aortic neck.
In two further cases with angulated necks and large an-
eurysms (b-angulation 60), the Nellix stents deviated
from their original deployment position during inﬂation of
the endobags. The stents were observed to separate during
endobag inﬂation, to move laterally towards the wall of a
large aneurysm, and pulled down in the aneurysm neck
leading to a more distal deployment than anticipated. In
subsequent cases, the Nellix balloons were kept inﬂated
during “preﬁll” and polymer ﬁll to stabilise position. This
technical modiﬁcation reduced the tendency for stents toTable 2. Aneurysm neck morphology in patients with proximal
Type 1 endoleak.
Neck length,
mm
Maximum neck
diameter, mm
b angulation, 
Patient 63 30 31 76
Patient 65 9 27 68
Patient 83 17 31 60
Patient 87 8 42 38separate during endobag ﬁll, and therefore reduced the
likelihood of distal stent migration.
All Type 1 endoleaks were treated by transcatheter em-
bolisation with Onyx (ev3, Irvine, CA, USA) and coils be-
tween 6 and 21 days after the primary EVAS procedure
(Fig. 3). Completion angiography following transcatheter
embolisation demonstrated technical success in all four
cases and post-procedure duplex showed no evidence of
residual endoleak.
There were no Type 1b, Type 2, or Type 3 endoleaks
within 30 days.
Adjunctive iliac stenting
A total of 62 (59%) patients underwent adjunctive iliac
stenting. The majority were bare metal self-expandable
stentgrafts (Zilver, Cook Medical) deployed in the pres-
ence of adverse angulation between the EVAS stentgraft
and the iliac vessel wall. Unilateral or bilateral iliac bare
stents were required in 36 (34%) and 19 (18%) patients,
respectively. Covered stents (Viabahn, Gore, Flagstaff, AZ,
USA; Advanta, Atrium Medical, Hudson, NH, USA) were
deployed unilaterally in 11 (11%) patients; one patient
required bilateral covered iliac stenting during EVAS. No
signiﬁcant difference was observed in the use of adjunctive
iliac stenting when comparing the ﬁrst and second halves of
the experience (p ¼ .78).
Limb reinterventions within 30 days
No immediate lower limb ischaemic complications occurred
as a result of balloon inﬂation during polymer cure. Three
patients underwent postoperative digital subtraction angi-
ography, angioplasty, and adjunctive stenting with Luminex
(Bard, Karsruhe, Germany) or Zilver (Cook Medical) for
unilateral limb stenoses of 50% based on ultrasound
duplex imaging. All three patients requiring limb reinter-
vention were treated within the ﬁrst 20 cases of the overall
experience, and, in retrospect, were caused by inadequate
stent dilatation during the original procedure and place-
ment of the distal limb at a site of potential kink. In later
cases, the Nellix balloons were kept inﬂated during polymer
cure to maximise the stent lumen, and post dilatation was
performed using 10  40 mm angioplasty balloons. In cases
where a potential kink was considered likely, self-expanding
stents were placed distally (Cook Medical).
There were no limb occlusions within 30 days.
Iatrogenic vascular injuries
Two patients experienced iatrogenic aortic injuries during
EVAS, both resulting from iliac injury during Nellix stent
deployment. Both patients had narrowed, diseased, and
calciﬁed iliac arteries. In the ﬁrst case, ﬁll pressure was lost
during the polymer instillation and an angiographic run
demonstrated a right common iliac rupture secondary to
stent deployment in a narrow, diseased common iliac artery.
The iliac rupture allowed the endobag to prolapse and
caused a loss of ﬁll pressure, with inadequate ﬁlling of the
aneurysm sac and an absence of sealing. Preferential ﬁlling
Figure 2. Insufﬁcient correction for parallax (A) and distal deployment of the Nellix stents (B).
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aneurysm and the iliac rupture site was treated with
deployment of a Viabahn (Gore) stent. Completion angi-
ography conﬁrmed sealing of the aneurysm and good distal
ﬂow (Fig. 4).
In the second case, the Nellix endografts were deployed
to 7atm and, following balloon inﬂation, the patient became
tachycardic and hypotensive. The angioplasty balloons were
kept inﬂated while the patient was resuscitated and a pri-
mary polymer ﬁll was performed. Following removal of the
devices, two 14-F sheaths were inserted and angioplasty
balloons inﬂated at the distal ends of the Nellix stents for
haemostasis. Angiographic runs through the sheaths
conﬁrmed iliac injury at the junction of the common andFigure 3. Proximal Type 1 endoleak (A) and treaexternal iliac arteries. Both injuries were treated with
deployment of covered stents (Viabahn, Gore) without
clinical sequelae.
DISCUSSION
Any new medical device will be associated with a spectrum
of complications that need to be deﬁned and managed. The
105 patients reported here represent the ﬁrst cohort of
patients treated at a single centre after the commerciali-
sation of the Nellix graft. At the time of the initiation of the
clinical programme, global experience with the Nellix graft
was limited, and technical aspects of the intraoperative
procedure evolved during the study period to improve
clinical outcomes.tment with transcatheter embolisation (B).
Figure 4. Iatrogenic injury to the right common iliac artery (A) and treatment with a covered stent (B).
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occurrence of high ﬂow endoleak and subsequent man-
agement is paramount. In the present series, four proximal
Type 1 endoleaks were observed within 30 days, all in pa-
tients with adverse proximal aortic neck anatomy. Following
insertion of Nellix endografts, proximal endoleaks are
observed between the polymer ﬁlled endobag and the
aneurysm sac, more lateral than those following treatment
with a bifurcated endograft. Type 1 endoleaks are best
identiﬁed in longitudinal plane; their appearance is mark-
edly different to a traditional endoleak after EVAR but is
characteristic.20
Two endoleaks appeared to be related to sub-optimal
graft deployment caused by insufﬁcient correction for
parallax, and technical modiﬁcation to the implant proce-
dure eradicated this error in later patients. Parallax
correction was facilitated by positioning the sheath markers
at the level of the renal arteries to ensure a perpendicular
tube position. Distal deployment of the stent in these two
cases meant that the endobag was applied to an insufﬁcient
length of proximal aortic neck and an endoleak ensued.
Two further proximal endoleaks were related to distal
endograft movement during endobag inﬂation and
appeared to be associated with a particular aneurysm
morphology. In aneurysms with a large ﬂow lumen and an
angulated neck, there appears to be a tendency for the
Nellix stents to move laterally and separate on endobag
inﬂation. This results in relative graft shortening, which may
cause the proximal end of the stent to move distally, or the
distal stent to move proximally. If the proximal stent section
moves distally, then there may be insufﬁcient application of
the endobag to the proximal neck and a Type 1a endoleak
will result. The position of the Nellix stents may be stabilised
by keeping the Nellix balloons inﬂated during the procedure
until the polymer has cured after the primary ﬁll.
All patients with endoleaks in the present series had
adverse proximal aortic neck anatomy. A similar trend has
been observed for EVAR, with adverse anatomy being
associated with higher perioperative mortality, reinterven-
tion, and graft thrombosis.22,23 Data from the EUROSTARregistry demonstrated that a neck length of <15 mm was
associated with signiﬁcantly increased rates of early (30
days) proximal type 1 endoleak.24 In EUROSTAR, 30-day
rates of Type 1a endoleak in patients with infrarenal neck
length of >15 mm, 11e15 mm, and 10 mm were 2.6%,
3.5%, and 10.9%, respectively.
One of the concerns of adopting EVAS is the potential
difﬁculty in treating proximal Type 1 endoleaks, as the
two-stent design means that insertion of a proximal aortic
cuff or a Palmaz stent would be difﬁcult. In the present
series, all proximal Type 1 endoleaks were treated with
onyx and coil embolisation. This technique is relatively
novel; however, two small series have shown promising
early results.25,26 Transcatheter embolisation procedures
performed in this series appeared to be successful, in
short-term follow-up, at sealing the endoleak. One draw-
back of Onyx embolisation is the beam-hardening artefact
present on follow-up CT, with resulting difﬁculty in visu-
alising endoleak. However, there was no evidence of re-
sidual endoleak on duplex evaluation.
Endovascular aneurysm sealing is a potentially disruptive
technology for the treatment of patients with AAA. Sealing
of the aneurysm sac may address some of the long-term
durability issues that affect EVAR. EVAS should greatly
reduce Type 2 endoleaks, which make surveillance chal-
lenging, and also stabilise the endograft, reducing migra-
tion, graft displacement, and structural failure.
Encouragingly, in the present series there were no early
Type 2 endoleaks.
Three haemodynamically signiﬁcant limb stenoses
(50%) occurred in the early stages of the overall experi-
ence. A potential explanation for the absence of this
complication in the remaining patients was the more liberal
use of adjunctive self-expanding bare metal stents at the
distal end of the Nellix limbs, where a potential for kinking
was clinically suspected. A further technical reﬁnement was
the maintenance of Nellix balloon inﬂation throughout
polymer curing to increase luminal diameter of the stents
by preventing any endobag prolapse through the interstices
of the balloon expandable stent.
Endovascular Aneurysm Sealing 163One of the fundamental features of EVAS with Nellix is
that the endobags are used to provide anatomical ﬁxation
in the aneurysm sac, as well as providing a proximal and
distal seal. As such there is a compromise between mini-
mising pressure in the aneurysm sac (to prevent iatrogenic
rupture) and ensuring sufﬁcient polymer ﬁll in the aortic
neck and iliac arteries. At present, a target pressure of
180 mmHg is used for polymer ﬁll, but there is still the
potential for aortic rupture as endobags are inﬂated. In
the present series, there were no iatrogenic aortic rup-
tures, but there were two iliac injuries caused by balloon
inﬂation of the Nellix stents in narrow, calciﬁed iliac ar-
teries. In the case that resulted in endobag prolapse, the
redundancy within the Nellix system was demonstrated as
the aneurysm was sealed using one endobag; however,
early clinical experience suggests that EVAS should be
used cautiously when the iliac arteries are narrow and
calciﬁed.
EVAS may be applicable to a broader range of
morphology compared with conventional EVAR devices,
thus expanding the patient population considered eligible
for endovascular treatment. In the present study, the ﬂex-
ibility offered by the two single Nellix stents facilitated
treatment of patients whose aortic morphology was outside
the recommended use of traditional bifurcated endovas-
cular grafts.14 In this evolving experience, the Nellix graft
seemed to be particularly suitable for patients with conical
necks as the endobag could be closely applied to the entire
length of the conical neck, thus elongating the potential seal
zone.
This study has several limitations. The data reﬂect a
single-centre experience and may not extrapolate to other
institutions.While the series represents a consecutive group
of patients treated with EVAS, infrarenal AAAs treated
during the study period were not treated exclusively with
Nellix. As such there is a potential for bias in patient se-
lection. This report includes data on the ﬁrst cases per-
formed at the study institution and therefore reﬂects the
learning curve and evolution of procedure. During the
study, some reﬁnements in technique occurred with a
tendency to deploy the Nellix stents more proximally, with
increased use of ballooning during polymer cure and
increasing use of adjunctive iliac stenting with accumulating
experience. In retrospect, some of the reinterventions may
have been averted with these technical reﬁnements.
In the present series, EVAS in a cohort of patients with
challenging aortic anatomy, was associated with low rates
of early endoleak and reintervention in patients treated for
infrarenal AAA. These data provide some evidence of the
safety and effectiveness of the Nellix device for infrarenal
AAA, especially in the obviation of Type 2 endoleak. Patients
with favourable and adverse aneurysm morphology can be
successfully treated with the Nellix device. However, there
appears to be an association between hostile neck anatomy
and the development of proximal type 1 endoleak. Me-
dium- and long-term outcomes with respect to aortic-
related complications and reintervention will determine
the widespread applicability of EVAS technology.CONFLICT OF INTEREST
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